Scaling AAV manufacturing to 1000 L: Strategies for robust and reproducible production

Scaling adeno-associated virus (AAV) manufacturing beyond process development volumes remains a critical challenge as therapies advance toward larger patient populations and commercialization. Success at small scale does not always translate to robust, reproducible performance at manufacturing scale.

In this webinar, we share a practical approach to scaling transient AAV production, using an integrated strategy that combines cell line, media, and bioreactor process design to enable consistent process performance from development through manufacturing scale.

You’ll see data from scale-up studies highlighting key process parameters, scalability considerations, and approaches to maintaining productivity and product quality during scale-up.

To bring an external perspective, we will also present a real-world case study developed in collaboration with MilliporeSigma’s viral vector CDMO, demonstrating successful implementation of an AAV process using the ELEVECTA™ transient cell line at 1000 L scale. The case study highlights how thoughtful process design and scalable technologies translate into manufacturing-ready performance.

Watch to learn practical strategies for de-risking AAV scale-up and accelerating your path toward large-scale production.

Key learning objectives:
• Identify critical considerations for scaling transient AAV to ≥ 200 L
• Understand strategies for maintaining process robustness, productivity, and product quality during scale-up
• Learn from a real-world 1000 L case study demonstrating successful implementation of a scalable AAV manufacturing process

To learn more about the ELEVECTA™ transient cell line, head to www.info.cytivalifesciences.com/elevecta-transient.html
To learn more about Xcellerex™ X-platform bioreactors, head to https://info.cytivalifesciences.com/aav-x-platform.html